Analysis and Validation of circRNA-miRNA Network in Regulating m

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

40 citing papers in PubMed, 50 citations in OpenAlex.

1. RNA‑binding proteins as epithelial transcriptome orchestrators in gastric cancer: Immune‑metabolic crosstalk and therapeutic vulnerability (Review).International journal of molecular medicine · 2026
   Review
2. Targeting m6A methylation for early diagnosis and precision medicine in hepatocellular carcinoma.Cancer cell international · 2025
   Review
3. Elevated CEP72 expression facilitates the progression of hepatocellular carcinoma and is associated with unfavorable outcomes.Discover oncology · 2025
   Article
4. Journal of gastrointestinal oncology · 2025
   Article
5. Recent Advances in the Mutual Regulation of m6A Modification and Non-Coding RNAs in Atherosclerosis.International journal of general medicine · 2025
   Review
6. The epitranscriptome meets non-coding RNA: m6A-mediated regulation in oncogenesis and therapy.Frontiers in cell and developmental biology · 2025
   Review
7. Single-cell and spatial transcriptomics reveal correlation between RNA methylation-related miRNA risk model and immune infiltration in hepatocellular carcinoma.Frontiers in oncology · 2025
   Article
8. RNA modifications in the progression of liver diseases: from fatty liver to cancer.Science China. Life sciences · 2024
   Review
9. The YTH domain-containing protein family: Emerging players in immunomodulation and tumour immunotherapy targets.Clinical and translational medicine · 2024
   Review
10. Cross-talk between circRNAs and m6A modifications in solid tumors.Journal of translational medicine · 2024
    Review
11. Non-coding RNA-Mediated N6-Methyladenosine (mNon-coding RNA research · 2024
    Review
12. Research Progress on the Role of Epigenetic Methylation Modification in Hepatocellular Carcinoma.Journal of hepatocellular carcinoma · 2024
    Review
13. Non-coding RNA methylation modifications in hepatocellular carcinoma: interactions and potential implications.Cell communication and signaling : CCS · 2023
    Review
14. The potential role and mechanism of circRNAs in foam cell formation.Non-coding RNA research · 2023
    Review
15. Overview of mJournal of cancer research and clinical oncology · 2023
    Review
16. Crosstalk between m6A and coding/non-coding RNA in cancer and detection methods of m6A modification residues.Aging · 2023
    Review
17. Biological function analysis of ARHGAP39 as an independent prognostic biomarker in hepatocellular carcinoma.Aging · 2023
    Article
18. RNA mMolecular oncology · 2023
    Review
19. The potential role of m6A reader YTHDF1 as diagnostic biomarker and the signaling pathways in tumorigenesis and metastasis in pan-cancer.Cell death discovery · 2023
    Review
20. The function and clinical implication of YTHDF1 in the human system development and cancer.Biomarker research · 2023
    Review

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

Authors and funding

3 authors at 2 institutions in 1 country.

Funding

No grant is acknowledged in the PubMed record.

Abstract

Indexed as